

AMBULATORY TREATMENT UNIT

Tocilizumab (Actemra, Tyenne) Infusion Order Set

□ = Optional Order • = Routine Order (Cross out and initial **BULLETED ORDERS** that do not apply)

ORDERS				
Date:	Time:	ICD 10 Code:		
Diagnosis:			☐ Giant Cell Arteritis	
Patient Name:			Date of Birth:	Weight : (kg)
Allergies:				
☑ Last TB Test Date TB Test Result *Initial TB Test required prior to first dose. Any subsequent testing optional, and to be ordered and evaluated by provider. Nurse to confirm negative test. If positive, nurse will hold therapy and contact provider.				
PRE-MEDICATIONS - When ordering a pretreatment medication, please select appropriate formulation. □ Acetaminophen - 650 mg, Oral: Tab. Give prior to treatment. □ diphenhydramine - 25 mg oral capsule - 25 mg, Oral: Cap, Give prior to treatment. □ Methylprednisolone (Solu-Medrol) - 40 mg, IV Push. Give prior to treatment.				
□ 4 mg/kg (□ 6 mg/kg (□ 8 mg/kg (□ Other	Not to exceed 600 mg	g) every 4 weeks infused over 1 hour g) every 4 weeks infused over 1 hour g) every 4 weeks infused over 1 hour	Labs Orders	
□ 4 mg/kg (□ 6 mg/kg (Not to exceed 600 mg	sing g) every 4 weeks infused over 1 hour g) every 4 weeks infused over 1 hour g) every 4 weeks infused over 1 hour		
NURSING CONSIDERATIONS				
 Do not administer Actemra and/or it's biosimilars in patients with active or suspected infection Treatment for Adverse Drug Reactions (for mild to moderate infusion reaction) Slow or stop infusion for 20 minutes Give: • Diphenhydramine (Benadryl) 25 mg slow IVP STAT (may repeat times 1) Acetaminophen (Tylenol) 650 mg PO STAT, if not already given as a "premedication". (Maximum acetaminophen doses of 4000 mg in 24 hours from all combined sources.) Methylprednisolone (Solu-Medrol) 125 mg IVP STAT Place O₂ PRN at 4 - 6 liters per nasal cannula STAT Vital signs with PO₂ every 5 minutes until stable Notify the physician of reaction. Request further orders as indicated. Complete adverse drug reaction PowerForm and document in the allergy profile for all drug reactions. 				
 By signing this document, the provider confirms that: Patient is not on any other biological disease-modifying anti-rheumatic drugs (DMARDs) such as TNF antagonists, IL-1R antagonists, anti-CD20 monoclonal antibodies and selective co-stimulation modulators due to possibility of increased immunosuppression leading to increased risk of infection Patient either is not pregnant or understands the potential for Actemra and/or it's biosimilars to cause fetal harm if pregnant That ordering provider is responsible for baseline ANC, platelet and AST/ALT/Liver monitoring to ensure patient eligible for Actemra and/or it's biosimilars administration. 				
Provider Signature:			Date:	
Provider Name and Credentials (please print):			Time:	
Office Phone:		Office Fax:		

